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Summary There is evidence that predisposition to cancer has a genetic component. Genetic models have suggested that there is at least
one highly penetrant gene predisposing to this disease. The oncogene MXI1 on chromosome band 10q24-25 is mutated in a proportion of
prostate tumours and loss of heterozygosity occurs at this site, suggesting the location of a tumour suppressor in this region. To investigate
the possibility that MXI1 may be involved in inherited susceptibility to prostate cancer, we have sequenced the HLH and ZIP regions of the
gene in 38 families with either three cases of prostate cancer or two affected siblings both diagnosed below the age of 67 years. These are
the areas within which mutations have been described in some sporadic prostate cancers. No mutations were found in these two important
coding regions and we therefore conclude that MXll does not make a major contribution to prostate cancer susceptibility.
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Prostate cancer is the second commonest cause ofcancer mortality
in men in the UK (OPCS figures, 1993). Its incidence is increasing
by more than 10% every 5 years (Coleman et al, 1993), even when
the effect of screening is taken into account, and approximately
13% of cases occur in men under 65 years. There is increasing
evidence that there is an inherited component to many of the
common cancers (Easton and Peto, 1990), and prostate cancer is
no exception. There are several lines ofevidence for this: familial
clustering ofprostate cancer has been observed, most dramatically
in the large prostate cancer kindreds described in Utah, USA
(Eeles and Cannon Albright, 1996); relatives of cases have an
increased relative risk of developing the disease compared with
relatives of control subjects in case-control studies (reviewed in
Eeles, 1995), and this has been confirmed in two cohort studies
(Goldgar et al, 1994; Gronberg et al, 1996). This relative risk
increases markedly when the age ofthe index case decreases orthe
number of affected subjects in a cluster increases, which is
evidence that this increase in risk has a genetic component.
Segregation analysis has led to the proposed model of at least one
highly penetrant gene (88% of the gene carriers would develop
prostate cancer by age 85 years), which accounts for 43% ofcases
diagnosed at less than 55 years (Carter et al, 1992). When prostate
cancer susceptibility genes are located, men at increased risk ofthe
disease, particularly at a younger age, will be able to be identified.
A prostate cancer susceptibility locus has recently been reported
on lq24-25 (Smith et al, 1996); however, this would only account
for 34% of families, and further susceptibility loci remain to be
identified.
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To date, with the exception of MEN2 due to RET (Mulligan et
al, 1994), all high-risk cancer predisposition genes are tumour
suppressors; one allele is inherited in a mutated form and tumour
development occurs when the remaining allele at the cancer
predisposition locus is inactivated by loss or mutation (Knudson,
1985). If prostate cancer follows the same model, candidates for
susceptibility genes would reside in the areas of loss of heterozy-
gosity (LOH) observed in prostate tumours.
The long arm of chromosome 10 is the fourth commonest area
demonstrating LOH in sporadic prostate cancers (reviewed in
Eeles, 1995). In a study of42 informative tumours, LOH at 10qter
was observed in 19% of cases (Steinberg et al, 1990) and, more
recently, Eagle et al (1995) documented mutation at the non-
deleted MXII locus, which is in this region, in four out of ten
prostate cancers that had LOH at 10q24-25. Furthermore, in one
sample with no cytogenetic abnormality, the MXII gene was
shown to be absent. The mutations are in the non-deleted HLH and
ZIP exons, which are the parts of the gene that code for the helix-
loop-helix and leucine zipper regions involved in protein dimer-
ization. This is needed for specificity of MXII action. However,
Gray et al (1995) subsequently failed to find any mutations in
MXI in tumour DNA from 37 prostate cancers.
The oncogene, MYC, has been shown to be overexpressed in
higher-grade prostate cancers (Buttyan et al, 1987) and the MXI1
(MAX interactor factor 1) protein coded by the MXII gene nega-
tively regulates MYC activity. MXII, MAX and MAD are all
members of a family of proteins involved in the transcriptional
control of MYC proteins. All three, together with MYC, are
members of a larger family of proteins called helix-loop-helix
leucine zipper (HLH-ZIP) transcription factors. Dimerization of
proteins within this family permits subsequent DNA binding, a
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Table 1 Primers
Primer location Primer sequence PCR product
size (bp)
MXI1 ZIP exon Forward 5'-CGC AAG CTT TGT TTG TAC TGG ACT ATA CAC 280
Reverse 5'-CGC GM TTC ATG UT AGT ATT TCA TTA GAG AAG
MXI1 HLH exon Forward 5'-CGC MG CTT TM CCA GAC TGT GCT GAT TTG 250
Reverse 5'-CGC GM TTC ACC AGA ACT GAG GGA ATT GTG
function mediated by a highly basic region adjacent to the HLH-
ZIP motif (Murre et al, 1989). MYC also has distinct transcrip-
tional activation domains, which modulate gene expression (Kato
et al, 1990). MAX forms heterodimers with MXI1 (Zervos et al,
1993) and this inhibits MYC function in two ways: first, by
sequestering MAX (preventing the formation of MAX-MYC
heterodimers); and, secondly, by competing with MAX-MYC
heterodimers forbinding to target sites (Zervos et al, 1993). Taken
together these observations indicate thatMXII is agood candidate
for a prostate cancer susceptibility gene.
The CRC/BPG UK Familial Prostate Cancer Study aims to
investigate the role ofgenetic susceptibility to prostate cancer. The
contribution of both low- and high-penetrance genes is being
studied. As part of the study of high-penetrance genes, prostate
cancer cases with an increased chance of harbouring a prostate
cancer susceptibility gene are being collected. Those clusters with
a relative risk of developing prostate cancer of greater than or
equal to four are targeted for collection. We have, therefore,
concentrated on collecting clusters of . 3 prostate cancers at any
age or related pairs, preferably where one is less than 65 years at
diagnosis. The first 38 ofthese clusters were analysed in this study
and MXII was sequenced fromgermline DNA as a candidate for a
prostate cancer susceptibility gene.
MATERIALS AND METHODS
DNA extraction
Samples (10 ml) of blood were collected from individuals and
stored in EDTA at -700C until required. For DNA extraction, the
method of Kunkel et al (1977) was used with the following modi-
fication. Four volumes ofcold water were initially added to whole
blood. The phenol-chloroform extraction step was omitted and the
'salting out' procedure ofMiller et al (1988) was used to clean and
retrieve the DNA. The DNA was washed in 70% ethanol and dried
briefly, dissolved in 0.2-0.3 ml of water and stored at-20°C.
Polymerase chain reaction (PCR)
Sample DNA (200 ng) was added to a reaction mixture consisting
of 1 x PCR buffer [Applied Biosystems; 10 mm Tris (pH 8.3),
50 mM potassium chloride], 3.8 mm magnesium chloride
(Applied Biosystems), 0.16 mm each dNTP (0.64 mm total;
Stratagene), 0.2 ,ug (approximately 22 pmol) of each appropriate
primer (Table 1) and 0.75 units of Taq polymerase (Applied
Biosystems). The total reaction mixture was made up with water
(BDH) to a volume of 50gl. The tubes were topped with approxi-
mately 40g1 of mineral oil (Sigma) and cycled in a Biometra or
Hybaid thermocycler. Thermocycling was programmed for a
'touchdown' procedure as follows: initial denaturation step 94°C
for 2 min followed by fourcycles of94°C for 1 min, 64°C for 30 s
Table 2 Patient characteristics
Identifier Age at Number of Age of other
number diagnosis of affected relative(s) in
(individual prostate relatives family
tested) cancer in (years)
Individual
analysed
(years)
PR3380.201 49 4 73, 70, uk*, 73
PRS2036.201 65 4 69,63,56,74
PR3658.201 43 3 87, 37, 72
PRS2015.205 65 3 70, 65, 67
PRS2018.201 67 3 69, 70, 67
PRS2051.201 72 3 60, 75, 77
PR3106.201 67 2 74,81
PR3382.201 71 2 87, 62
PRS2016.201 64 2 73,60
PRS2024.201 56 2 38, 87
PRS2025.202 71 2 75, 65
PRS2031.202 59 2 67, 80
PRS2039.201 66 2 uk*, uk*
PRS2045.201 71 2 86,67
PRS2053.201 71 2 72, 77
PRS2059.201 76 2 71,81
PRY1061.201 49 2 58,61
PR3173.201 63 1 64
PR3222.201 58 1 82
PR3378.201 59 1 71
PR3498.201 61 1 64
PR3569.201 54 1 72
PRS2001.201 62 1 64
PRS2003.201 62 1 64
PRS2005.202 63 1 66
PRS2010.201 60 1 63
PRS2012.201 62 1 62
PRS2017.202 60 1 66
PRS2047.201 64 1 64
PRS2052.201 57 1 66
PRS2058.201 67 1 72
PRY1010.201 49 1 66
PRY1026.201 52 1 65
PRY1042.201 54 1 48
PRY1052.201 54 1 78
PRY1056.201 53 1 uk*
PRY1064.201 49 1 69
PRY1081.201 46 1 58
*Age unknown.
and 70°C for 1 min. The annealing temperature was reduced by
2°C every four cycles, until the annealing temperature was 56°C.
Samples were then given 24 cycles of 94°C for 1 min, 54°C for
30 s and 700C for 1 min, followed by a final polymerization of
700C for 10 min. A 5-,ul aliquot ofPCR reaction mixture was run
on a 2% agarose gel to check for the presence of the required
product.
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Figure 1 CRC/BPG UK Familial Prostate Cancer Study. Prostate family pedigrees with three or more cases of prostate cancer in this study. Ages shown are
age at diagnosis and current age/age at death. PRCA, prostate cancer; Ml, myocardial infarction; PE, pulmonary embolus; SCC, squamous cell carcinoma.
Arrowed case: individual whose DNA was sequenced
PCR products were purified before dye terminator cycle
sequencing according to Hamoudi et al (1996). The DNA was
dissolved in 12-15 p1 ofwaterand 3-4gl was run on a 2% agarose
gel to check for the presence and purity ofthe product.
Cycle sequencing
PCR products were purified as above and sequenced directly using
an ABI prism dye terminator cycle sequencing ready reaction kit
(Perkin Elmer), as recommended in the instructions, with thermo-
cycling as follows: 25 cycles of 96°C for 30 s, 50°C for 15 s and
60°C for 4 min. After thermocycling, the extension products were
removed from beneath the oil and added to 2 p1 of 3 M sodium
acetate, pH 5.2, precipitated with 50gd of absolute ethanol and
centrifuged. The pellet was washed with 70% ethanol, dried, then
stored at-20°C before automated sequencing.
Automated sequencing
The HLH and ZIP exons of the MXII gene were sequenced both
in the forward and reverse directions using the appropriate
primer shown in Table 1. Sequencing was conducted on a 6%
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Figure 1 continued
polyacrylamide denaturing gel (Biorad) in a 1 x TBE (Tris borate
buffer) using an ABI 373A automated fluorescent DNA sequencer.
The DNA pellet was dissolved in 4 jl offormamide. This mix was
denatured for 2 min at 92°C and loaded into each well. The gel
was run for 10 h at 30 W, 40 mA and 2500 V. During electro-
phoresis, the fluorescence was detected in the laser scanner region
using filter set A and data were collected and stored using the
DNA Sequencing Analysis Software (v.1.2; ABI, CA, USA). On
completion of the gel run, the data were analysed further using
Factura and Sequence Navigator software (ABI).
PATIENTS, RESULTS AND DISCUSSION
Patients
Individuals with prostate cancer were identified by their urologist
and referred to the CRC/BPG UK Familial Prostate Cancer Study.
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Figure 1 continued
Ofthese, 97% had disease thatpresented clinically; one presented as
a result of PSA screening. Diagnoses were confirmed by pathology
report or death certificate. A total of38 patients with prostate cancer
were studied; each patient had at least one other relative diagnosed
with prostate cancer. The family member who was chosen for inves-
tigation was the youngest at diagnosis for whom DNA was avail-
able. The clusters were as follows: two families had five cases, four
had four, 11 had three and 21 had two cases of prostate cancer.
Those with two cases in all but one cluster had one affected at less
than 65 years. Table 2 shows the details of each patient studied.
Where there are more than two individuals with prostate cancer in a
family, their family tree is shown in Figure 1.
The relative risk of prostate cancer to first-degree relatives
of prostate cancer patients diagnosed below age 65 years is
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Figure 1 continued
approximately fourfold, i.e. the number of cases with an affected
relative is four times the number that would be expected by
chance. Thus, of the cases diagnosed below age 65 years with an
affected relative, one-quarter of these relative pairs occur by
chance (or, in general, 1/relative risk). Thus, among the 21 related
pairs in which one case is diagnosed below age 65 years, approxi-
mately 25% will have occurred by chance and 75% will result
from genetic or other familial factors. The 17 families with
three or more cases of prostate cancer are less likely to have
occurred by chance; therefore, at least 75% of cases must be
caused by either genetic susceptibility or shared environmental
risk factors.
The ZIP and HLH exons ofMXII were sequenced in both direc-
tions in all 38 samples No mutations were found in either region
and the mutations reported by Eagle et al (1995), which included
one intronic mutation, were not observed. On the basis of these
observations, the upper 95% confidence limit for the proportion of
families with MXII mutations in ZIP and HLH would be 7.6% and
therefore, assuming that familial prostate cancer is mediated by a
single dominantgene aspredictedbythe Cartermodel,MXII muta-
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tion in these regions could be responsible for at most 10% ofhigh-
risk families. These are the only regions that have been reported to
be mutated in sporadic tumours. It is therefore very unlikely that
MXII is a prostate cancer susceptibility locus, PRCAJ.
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